Azacitidine is removed effectively by hemodialysis.

A hemodialysis patient with higher-risk myelodysplastic syndrome treated with standard-dose azacitidine. Azacitidine for injection (AZA) (Vidaza, Celgene Corp., Summit, NJ), represents a well-established and registered agent in Myelodysplastic Syndromes (MDS) and in acute myeloid leukemia (AML) [[1]]. In hemodialysis patients there are only a few case reports of administration of AZA and to our knowledge it has never been investigated to which extent AZA is removed by hemodialysis [[14]]. [Extracted from the article]